Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.
Knödler M, Körfer J, Kunzmann V, Trojan J, Daum S, Schenk M, Kullmann F, Schroll S, Behringer D, Stahl M, Al-Batran SE, Hacker U, Ibach S, Lindhofer H, Lordick F.
Knödler M, et al. Among authors: kullmann f.
Br J Cancer. 2018 Aug;119(3):296-302. doi: 10.1038/s41416-018-0150-6. Epub 2018 Jul 10.
Br J Cancer. 2018.
PMID: 29988111
Free PMC article.
Clinical Trial.